Want to see TLSI full AI Analyst Report?
Total Valuation
TriSalus Life Sciences has a market cap or net worth of $343.59M. The enterprise value is $253.39.
Market Cap$343.59M
Enterprise Value$253.39
Share Statistics
TriSalus Life Sciences has 61,574,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,574,600
Owned by Insiders28.15%
Owned by Institutions2.20%
Financial Efficiency
TriSalus Life Sciences’s return on equity (ROE) is 1.16 and return on invested capital (ROIC) is -112.28%.
Return on Equity (ROE)1.16
Return on Assets (ROA)-1.11
Return on Invested Capital (ROIC)-112.28%
Return on Capital Employed (ROCE)-1.13
Revenue Per Employee442.66K
Profits Per Employee-384.58K
Employee Count102
Asset Turnover1.28
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of TriSalus Life Sciences is ―. TriSalus Life Sciences’s PEG ratio is -0.08.
PE Ratio―
PS Ratio7.60
PB Ratio-10.14
Price to Fair Value-10.14
Price to FCF-18.14
Price to Operating Cash Flow-11.43
PEG Ratio-0.08
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 45.15M and earned -39.23M in profits. Earnings per share was -1.84.
Revenue45.15M
Gross Profit38.19M
Operating Income-26.95M
Pretax Income-39.22M
Net Income-39.23M
EBITDA-33.05M
Earnings Per Share (EPS)-1.84
Cash Flow
In the last 12 months, operating cash flow was -29.28M and capital expenditures -621.00K, giving a free cash flow of -29.90M billion.
Operating Cash Flow-29.28M
Free Cash Flow-29.90M
Free Cash Flow per Share-0.49
Dividends & Yields
TriSalus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change57.26%
50-Day Moving Average4.17
200-Day Moving Average4.78
Relative Strength Index (RSI)74.71
Average Volume (3m)399.91K
Important Dates
TriSalus Life Sciences upcoming earnings date is Nov 12, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
TriSalus Life Sciences as a current ratio of 2.80, with Debt / Equity ratio of 525.59%
Current Ratio2.80
Quick Ratio2.54
Debt to Market Cap0.10
Net Debt to EBITDA-0.42
Interest Coverage Ratio-4.86
Taxes
In the past 12 months, TriSalus Life Sciences has paid 7.00K in taxes.
Income Tax7.00K
Effective Tax Rate>-0.01
Enterprise Valuation
TriSalus Life Sciences EV to EBITDA ratio is -10.81, with an EV/FCF ratio of -18.88.
EV to Sales7.91
EV to EBITDA-10.81
EV to Free Cash Flow-18.88
EV to Operating Cash Flow-19.84
Balance Sheet
TriSalus Life Sciences has $46.29M in cash and marketable securities with $34.43M in debt, giving a net cash position of $11.86M billion.
Cash & Marketable Securities$46.29M
Total Debt$34.43M
Net Cash$11.86M
Net Cash Per Share$0.19
Tangible Book Value Per Share-$0.69
Margins
Gross margin is 85.79%, with operating margin of -59.68%, and net profit margin of -86.88%.
Gross Margin85.79%
Operating Margin-59.68%
Pretax Margin-86.86%
Net Profit Margin-86.88%
EBITDA Margin-73.20%
EBIT Margin-74.59%
Analyst Forecast
The average price target for TriSalus Life Sciences is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.00
Price Target Upside136.97% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast25.25%
EPS Growth Forecast-9.85%